Pulmonary Manifestations of Polymyositis/Dermatomyositis

Abstract

The idiopathic inflammatory myopathies are a group of connective tissue diseases marked by varying degrees of muscle inflammation and clinical involvement of multiple organs, most notably, the lung. Pulmonary manifestations consist primarily of interstitial lung disease (ILD), which is associated with significant morbidity and mortality in myositis patients. Several myositis-specific antibodies have been discovered, as well as antibodies targeting various aminoacyl-tRNA synthetase enzymes. These antibodies are associated with various clinical features and a risk for developing ILD, and their presence carries a prognostic value in myositis patients. Steroids remain the first-line treatment for myositis-associated ILD and the antisynthetase syndrome, though other traditional immunosuppressants have demonstrated efficacy in numerous studies. While a majority of patients experience either stabilization or improvement in lung imaging and function, fatal progression is still reported in a significant number of cases. Further research is needed to develop more effective and targeted therapies.

Keywords

idiopathic inflammatory myopathies - polymyositis - dermatomyositis - interstitial lung disease - nonspecific interstitial pneumonia - myositis-specific autoantibodies

• References

• 1 Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine L, Danoff SK, Oddis CV. Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rep 2010; 6 (2) 108-119
• 2 Chen IJ, Jan Wu YJ, Lin CW , et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 2009; 28 (6) 639-646
• 3 Ye S, Chen XX, Lu XY , et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 2007; 26 (10) 1647-1654
• 4 Won Huh J, Soon Kim D, Keun Lee C , et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 2007; 101 (8) 1761-1769
• 5 Hayashi S, Tanaka M, Kobayashi H , et al. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. J Rheumatol 2008; 35 (2) 260-269
• 6 Yu KH, Wu YJ, Kuo CF , et al. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol 2011; 30 (12) 1595-1601
• 7 Ji SY, Zeng FQ, Guo Q , et al. Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study. Chin Med J (Engl) 2010; 123 (5) 517-522
• 8 Fathi M, Vikgren J, Boijsen M , et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008; 59 (5) 677-685
• 9 Chua F, Higton AM, Colebatch AN , et al. Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort. Rheumatology (Oxford) 2012; 51 (10) 1870-1876
• 10 Lee CS, Chen TL, Tzen CY , et al. Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol 2002; 21 (5) 391-396
• 11 Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004; 63 (3) 297-301
• 12 Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292 (8) 403-407
• 13 Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292 (7) 344-347
• 14 Koreeda Y, Higashimoto I, Yamamoto M , et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med 2010; 49 (5) 361-369
• 15 Marie I, Josse S, Hatron PY , et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 2013; 65 (5) 800-808
• 16 Sato S, Hirakata M, Kuwana M , et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52 (5) 1571-1576
• 17 Kaji K, Fujimoto M, Hasegawa M , et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46 (1) 25-28
• 18 Brouwer R, Hengstman GJ, Vree Egberts W , et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001; 60 (2) 116-123
• 19 Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50 (1) 209-215
• 20 Dugar M, Cox S, Limaye V, Blumbergs P, Roberts-Thomson PJ. Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies. Intern Med J 2011; 41 (9) 674-679
• 21 Kalluri M, Sahn SA, Oddis CV , et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 2009; 135 (6) 1550-1556
• 22 Hirakata M, Suwa A, Nagai S , et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999; 162 (4) 2315-2320
• 23 Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) 2007; 46 (6) 1005-1008
• 24 Kunimasa K, Arita M, Nakazawa T , et al. The clinical characteristics of two anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibody-positive interstitial lung disease patients with polymyositis/dermatomyositis. Intern Med 2012; 51 (24) 3405-3410
• 25 Hervier B, Meyer A, Dieval C , et al. Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. Eur Respir J 2013; 42 (5) 1271-1282
• 26 Marie I, Josse S, Decaux O , et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 2012; 11 (10) 739-745
• 27 Hamaguchi Y, Fujimoto M, Matsushita T , et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS ONE 2013; 8 (4) e60442
• 28 Hall JC, Casciola-Rosen L, Samedy LA , et al. Anti-MDA5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 2013; 65 (8) 1307-1315
• 29 Hervier B, Benveniste O. Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep 2013; 15 (8) 349
• 30 Gono T, Kawaguchi Y, Kuwana M , et al. Brief report: association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum 2012; 64 (11) 3736-3740
• 31 Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007; 19 (6) 523-529
• 32 Marie I, Hatron PY, Dominique S , et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 2012; 41 (6) 890-899
• 33 Richards TJ, Eggebeen A, Gibson K , et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum 2009; 60 (7) 2183-2192
• 34 Marie I, Josse S, Decaux O , et al. Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome. Eur J Intern Med 2013; 24 (5) 474-479
• 35 Hervier B, Wallaert B, Hachulla E , et al. Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology (Oxford) 2010; 49 (5) 972-976
• 36 Sato S, Hoshino K, Satoh T , et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60 (7) 2193-2200
• 37 Chen F, Wang D, Shu X, Nakashima R, Wang G. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int 2012; 32 (12) 3909-3915
• 38 Cao H, Pan M, Kang Y , et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken) 2012; 64 (10) 1602-1610
• 39 Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65 (1) 25-34
• 40 Kang EH, Nakashima R, Mimori T , et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 2010; 11: 223
• 41 Koga T, Fujikawa K, Horai Y , et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 2012; 51 (7) 1278-1284
• 42 Fujikawa K, Kawakami A, Kaji K , et al. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol 2009; 38 (4) 263-267
• 43 Gono T, Sato S, Kawaguchi Y , et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) 2012; 51 (9) 1563-1570
• 44 Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 2010; 49 (9) 1726-1733
• 45 Ikeda N, Takahashi K, Yamaguchi Y, Inasaka M, Kuwana M, Ikezawa Z. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol 2011; 38 (10) 973-979
• 46 Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford) 2012; 51 (5) 800-804
• 47 Sato S, Kuwana M, Fujita T, Suzuki Y. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Mod Rheumatol 2012; 22 (4) 625-629
• 48 Selva-O'Callaghan A, Labrador-Horrillo M, Solans-Laque R, Simeon-Aznar CP, Martínez-Gómez X, Vilardell-Tarrés M. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum 2006; 55 (5) 791-798
• 49 Venables PJ. Polymyositis-associated overlap syndromes. Br J Rheumatol 1996; 35 (4) 305-306
• 50 Lega JC, Cottin V, Fabien N, Thivolet-Béjui F, Cordier JF. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?. J Rheumatol 2010; 37 (5) 1000-1009
• 51 Ferreira JP, Almeida I, Marinho A, Cerveira C, Vasconcelos C. Anti-ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma. ISRN Rheumatol 2012; 2012: 415272
• 52 Rutjes SA, Vree Egberts WT, Jongen P, Van Den Hoogen F, Pruijn GJ, Van Venrooij WJ. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997; 109 (1) 32-40
• 53 Dugar M, Cox S, Limaye V, Gordon TP, Roberts-Thomson PJ. Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad Med J 2010; 86 (1012) 79-82
• 54 La Corte R, Lo Mo Naco A, Locaputo A, Dolzani F, Trotta F. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 2006; 39 (3) 249-253
• 55 Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 2009; 48 (6) 607-612
• 56 Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990; 33 (9) 1361-1370
• 57 Hengstman GJ, ter Laak HJ, Vree Egberts WT , et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006; 65 (12) 1635-1638
• 58 Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73 (4) 420-428
• 59 Hengstman GJ, Vree Egberts WT, Seelig HP , et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 2006; 65 (2) 242-245
• 60 Wang HB, Zhang Y. Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor. Nucleic Acids Res 2001; 29 (12) 2517-2521
• 61 Chinoy H, Salway F, Fertig N , et al; UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC). In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006; 8 (1) R13
• 62 Gono T, Kawaguchi Y, Satoh T , et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 2010; 49 (9) 1713-1719
• 63 Tanizawa K, Handa T, Nakashima R , et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med 2013; 107 (5) 745-752
• 64 Ideura G, Hanaoka M, Koizumi T , et al. Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases. Respir Med 2007; 101 (7) 1406-1411
• 65 Fujisawa T, Suda T, Nakamura Y , et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 2005; 32 (1) 58-64
• 66 Hervier B, Devilliers H, Stanciu R , et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 2012; 12 (2) 210-217
• 67 Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011; 63 (11) 3439-3447
• 68 Fathi M, Barbasso Helmers S, Lundberg IE. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med 2012; 271 (6) 589-597
• 69 Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?. Chest 2010; 138 (6) 1464-1474
• 70 Le Goff B, Chérin P, Cantagrel A , et al. Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. Arthritis Rheum 2009; 61 (1) 108-118
• 71 Kono H, Inokuma S, Nakayama H, Suzuki M. Pneumomediastinum in dermatomyositis: association with cutaneous vasculopathy. Ann Rheum Dis 2000; 59 (5) 372-376
• 72 Korkmaz C, Ozkan R, Akay M, Hakan T. Pneumomediastinum and subcutaneous emphysema associated with dermatomyositis. Rheumatology (Oxford) 2001; 40 (4) 476-478
• 73 Maruoka H, Honda S, Takeo M , et al. A case of polymyositis complicated with interstitial pneumonitis and pneumomediastinum. Mod Rheumatol 2006; 16 (1) 55-57
• 74 Park SH, Kum YS, Kim KC, Choe JY, Park SH, Kim SK. Pneumomediastinum and subcutaneous emphysema secondary to amyopathic dermatomyositis with cryptogenic organizing pneumonia in invasive breast cancer: a case report and review of literature. Rheumatol Int 2009; 29 (10) 1231-1235
• 75 Powell C, Kendall B, Wernick R, Heffner JE. A 34-year-old man with amyopathic dermatomyositis and rapidly progressive dyspnea with facial swelling. Diagnosis: pneumomediastinum and subcutaneous emphysema secondary to amyopathic dermatomyositis-associated interstitial lung disease. Chest 2007; 132 (5) 1710-1713
• 76 Sandhya P, Keshava SN, Danda D, Padhan P, Mathew J, Gibikote S. Pneumorrhachis and pneumomediastinum in connective tissue disease-related interstitial lung disease: case series from a tertiary care teaching hospital in South India. Rheumatol Int 2012; 32 (5) 1415-1419
• 77 Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies. Rheumatology (Oxford) 2007; 46 (5) 842-845
• 78 Yoshifuji H, Fujii T, Kobayashi S , et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006; 39 (3) 233-241
• 79 Hamaguchi Y, Kuwana M, Hoshino K , et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 2011; 147 (4) 391-398
• 80 Kameda H, Nagasawa H, Ogawa H , et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005; 32 (9) 1719-1726
• 81 Swigris JJ, Olson AL, Fischer A , et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130 (1) 30-36
• 82 Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 2010; 62 (10) 1496-1501
• 83 Yamasaki Y, Yamada H, Yamasaki M , et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007; 46 (1) 124-130
• 84 Ingegnoli F, Lubatti C, Ingegnoli A, Boracchi P, Zeni S, Meroni PL. Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. Autoimmun Rev 2012; 11 (5) 335-340
• 85 Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005; 38 (5) 383-392
• 86 Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52 (8) 2439-2446
• 87 Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009; 48 (8) 968-971
• 88 Park JK, Yoo HG, Ahn DS, Jeon HS, Yoo WH. Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab. Rheumatol Int 2012; 32 (11) 3587-3590
• 89 Suzuki Y, Hayakawa H, Miwa S , et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 2009; 187 (3) 201-206
• 90 Bakewell CJ, Raghu G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest 2011; 139 (2) 441-443
• 91 Gono T, Kawaguchi Y, Hara M , et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 2010; 49 (7) 1354-1360
• 92 Tillie-Leblond I, Wislez M, Valeyre D , et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008; 63 (1) 53-59
• 93 Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007; 9 (4) R78
• 94 Mukae H, Ishimoto H, Sakamoto N , et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 2009; 136: 1341-1347